T Cells in Type 1 Diabetes Cross-React Between Insulin and Hybrid Peptides Containing Neuropeptide Y Fragments | Research

The takeaway

Diabetogenic T cell clones cross-react between native proinsulin and hybrid insulin peptides fused to neuropeptide Y and IAPP fragments, with crystal structures revealing distinct TCR recognition mechanisms.

5/7 TCRs cross-reactive
diabetogenic T cell clones recognized both proinsulin and hybrid insulin peptides with NPY fragments

What the researchers found

Five of seven diabetogenic TCRs cross-reacted between proinsulin C-peptide and hybrid insulin peptides containing NPY and IAPP fragments, with structural studies revealing position-specific determinants of cross-reactivity at P2, P7, and P8.

Why it matters

Understanding how diabetogenic T cells recognize and cross-react with hybrid peptides reveals fundamental mechanisms of autoimmune diabetes and could guide the development of peptide-based tolerizing therapies or vaccines.

The numbers in context

Two peptides studied: PI40-54 (proinsulin C-peptide) and HIP PI40-47-IAPP74-80 (hybrid insulin peptide); presented by HLA-DQ8.

How the study worked

T cell activation assays with SKW3 cell lines expressing diabetogenic TCRs, crystal structures of TCR-peptide-HLA-DQ8 complexes, and alanine scanning mutagenesis to identify key recognition residues.

Who was studied

Human islet-infiltrating T cell clones and crystallographic analysis

What this study cannot tell us

T cell lines from a small number of patients; SKW3 cell system may not fully represent natural T cell responses; crystal structures represent static snapshots; limited HIP variants tested; HLA-DQ8-restricted findings may not generalize to other HLA types.

How to read the evidence

Strong mechanistic evidence combining functional immunology with structural biology, though limited by small numbers of patient-derived T cell clones.

When this study was published

Published in 2024, advancing understanding of hybrid insulin peptide cross-reactivity in type 1 diabetes autoimmunity.

The bigger picture

Hybrid insulin peptides are a relatively new concept in autoimmunity. This study shows that the immune system's confusion between normal proinsulin and these hybrid peptides involving neuropeptide Y fragments may be a key driver of type 1 diabetes — potentially offering new therapeutic targets.

Questions still open

Could tolerizing patients to these specific hybrid peptides prevent type 1 diabetes progression?
Do HIPs containing NPY fragments form naturally in the pancreas of pre-diabetic individuals?
How prevalent is cross-reactive T cell recognition of these HIPs across the type 1 diabetes patient population?

Common questions

How do hybrid insulin peptides contribute to type 1 diabetes?

In the pancreas, fragments of different proteins (including proinsulin, neuropeptide Y, and IAPP) can fuse together creating hybrid peptides. This study shows that immune T cells trained to recognize one of these peptides can mistakenly attack cells presenting the others — potentially accelerating the autoimmune destruction of insulin-producing cells.

Could this research lead to a type 1 diabetes vaccine?

Potentially — by understanding exactly which peptide fragments the immune system confuses, researchers could design tolerance-inducing vaccines that teach the immune system to stop attacking these targets, possibly preventing or slowing type 1 diabetes.

Read the original research

A structural basis of T cell cross-reactivity to native and spliced self-antigens presented by HLA-DQ8.

The Journal of biological chemistry, 300(9), 107612

View on PubMed ↗Publisher’s paper ↗

Citation

Tran, Mai T; Lim, Jia Jia; Loh, Tiing Jen; Mannering, Stuart I; Rossjohn, Jamie; Reid, Hugh H. (2024). A structural basis of T cell cross-reactivity to native and spliced self-antigens presented by HLA-DQ8.. The Journal of biological chemistry, 300(9), 107612. https://doi.org/10.1016/j.jbc.2024.107612